Why the study?
Does the risk of anticoagulant-induced intracerebral bleeding differ among patients with TIAs, embolic brain ischemia, and progressing stroke receiving intravenous heparin?
Does the risk of anticoagulant-induced intracerebral bleeding differ among patients with TIAs, embolic brain ischemia, and progressing stroke receiving intravenous heparin?
The risk and prognostic impact of anticoagulant-induced intracerebral bleeding vary significantly depending on the type of preceding ischemic event, with progressing stroke carrying the highest bleeding risk.
Answers are grounded in this paper and cite their sources.
May warrant heparin caution in progressing stroke; leaves open whether bleeding risk differs meaningfully by ischemic subtype.
During a 5-year period, 85 patients with TIAs, 65 patients with embolic brain ischemia of cardiac source and 50 patients with progressing stroke received intravenous heparin within 96 h. Twelve (6%) developed an early bleeding in the area involved by ischemia. In the 2 cases with transient ischemic attacks (TIAs) (2.3%), major functional sequelae persisted and the 2 cases with emboli from heart (3.2%) died, whereas among the 8 cases with progressing stroke (16%), only 3 worsened from anticoagulant-induced bleeding. Intracerebral bleeding was not associated with excessive anticoagulation or high blood pressure and was related to a large infarction only in the cases with emboli from the heart. Among the 108 patients who were placed on acenocoumarol during 3-12 months after heparin therapy, only one (0.9%) suffered a hemorrhagic infarct from a probable recurrent embolization. The risk of anticoagulant-induced intracerebral bleeding is quite different between the varieties of preceding ischemic events, with different subsequent impact on prognosis.
No takes yet. Share an insight, caveat, or question.
Bogousslavsky et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: